DEVELOPMENT AND EVALUATION OF FAVIPIRAVIR AGGLOMERATES FOR DIRECT COMPRESSION BY CRYSTALLO-CO-AGGLOMERATION TECHNIQUE

During the severe worldwide pandemic caused due to SARS COV-2 Corona virus, Favipiravir has been used for the treatment. It is a water insoluble anti-viral drug with poor dissolution and poor flow properties, resulting in poor oral absorption and less bioavailability. For a long time, the phrase “direct compression” was used to describe the compression of a single crystalline component into a compact without the addition of any other materials. Using excipients and solvents, the crystallo-co-agglomeration process aggregates drug crystals in the form of small spherical particles to create an intermediate product with better micromeritic and mechanical characteristics, solubility, and dissolution. Crystallo-co-agglomeration is a unique approach in which the pharmaceuticals or excipients are crystallized and agglomerated concurrently from a good solvent and/or bridging liquid by adding a non-solvent. The present study aims to formulate crystallo-co-agglomerates of Favipiravir to improve its physicochemical and mechanical properties. Results obtained during the evaluation showed that CCA technique could be successfully employed as an alternative to conventional wet agglomeration.